Lilly Asia Ventures
Jieyu Zou, is a Managing Director with Lilly Asia Ventures (LAV). Prior to joining LAV, she was an investment manager in Fosun healthcare group. Prior to that, she worked as a research associate in Michael Allen Company, providing consulting service to clients from leading pharmaceutical companies. Jieyu holds a M.P.H. degree from Yale University School of Public Health and her dual bachelor’s in Biology and Psychology from Peking University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.